SECAUCUS, NJ / ACCESSWIRE / February 27, 2024 / Quest Diagnostics (NYSE:DGX), the nation’s leading provider of diagnostic information services, announced that it has been selected as one of FORTUNE’s World’s Most Admired Companies in 2024 for the tenth consecutive year.
Fortune’s World’s Most Admired Companies recognition is based on nine criteria of corporate reputation, from innovation and quality of management and products, to social responsibility and people management.
“I’m grateful to our dedicated Quest colleagues for making this possible,” said Jim Davis, Chairman, CEO and President. “They are the heart and soul of this company. Every day our colleagues bring our purpose to life, working together to create a healthier world, one life at a time. It is an honor to be named one of Fortune World’s Most Admired Companies for the last decade.”
The annual survey designated Quest as one of only five companies to attain Most Admired status in the “Health Care: Pharmacy and Other Services” industry. The company scored high marks in people management, use of corporate assets and social responsibility.
To determine the rankings, Fortune partnered with global organizational consulting firm Korn Ferry to survey thousands of executives, directors and analysts who rated companies in their industry based on nine criteria. The survey included a total of 660 companies from 29 countries.
Find the full 2024 list of FORTUNE’s World’s Most Admired Companies here.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
For further information: For further information: Jennifer Petrella, Quest Diagnostics (Media): 973-520-2800 or mediacontact@QuestDiagnostics.com; Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info:
Spokesperson: Quest Diagnostics
Website: https://www.3blmedia.com/profiles/quest-diagnostics
Email: info@3blmedia.com
SOURCE: Quest Diagnostics
View the original press release on accesswire.com
Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…
CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…
MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…
Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…